News
Eric Green, M.D., Ph.D., formerly the NHGRI director, has been awarded by Fierce Pharma as a Fierce 50 Innovation Honoree. The Fierce 50 is designed to honor the 50 most influential leaders and organizations shaping the future of biopharma, healthcare, and life sciences. The Fierce editorial team
Traumatic Brain Injuries (TBI) are a major cause of death and disability. Current therapies to treat TBIs with neuroprotective agents are often limited by ability to achieve therapeutic concentrations of the therapeutic agent in the brain. Inventors at the National Institute of Neurological
Primary mediastinal B-cell lymphoma (PMBCL) is a non-Hodgkin lymphoma that accounts for 5-7% of all aggressive lymphomas. Diagnosing PMBCL can be challenging as the features overlap with diffuse large B-cell lymphoma (DLBCL), another type of non-Hodgkin lymphoma. These two lymphomas respond
Researchers at the National Cancer Institute (NCI) have developed a diagnostic assay that detects sequence-specific (viral) RNA. This technology describes an RNase-H-assisted detection assay for RNA (RADAR) that is rapid, inexpensive, and highly sequence-specific. There is a great need for this